Talphera (NASDAQ:TLPH) Upgraded at RODMAN&RENSHAW

RODMAN&RENSHAW upgraded shares of Talphera (NASDAQ:TLPH) to a strong-buy rating in a report published on Tuesday,Zacks.com reports.

A number of other equities analysts have also commented on the company. HC Wainwright reiterated a “buy” rating and issued a $6.00 price objective on shares of Talphera in a research note on Tuesday, January 21st. Rodman & Renshaw initiated coverage on Talphera in a report on Tuesday. They issued a “buy” rating and a $4.00 target price on the stock. Finally, Maxim Group upgraded Talphera to a “strong-buy” rating in a report on Friday, November 8th.

Talphera Trading Down 1.0 %

NASDAQ TLPH opened at $0.69 on Tuesday. The company has a market cap of $11.82 million, a P/E ratio of -1.01 and a beta of 0.28. Talphera has a 1 year low of $0.50 and a 1 year high of $1.61. The company has a fifty day simple moving average of $0.65 and a 200 day simple moving average of $0.81.

Hedge Funds Weigh In On Talphera

A hedge fund recently bought a new stake in Talphera stock. Rosalind Advisors Inc. bought a new stake in Talphera, Inc. (NASDAQ:TLPH) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 758,966 shares of the company’s stock, valued at approximately $650,000. Talphera makes up approximately 0.4% of Rosalind Advisors Inc.’s investment portfolio, making the stock its 25th biggest position. Rosalind Advisors Inc. owned 4.47% of Talphera at the end of the most recent reporting period. Institutional investors own 37.67% of the company’s stock.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.